In its upcoming report, McKesson (MCK) is predicted by Wall Street analysts to post quarterly earnings of $6.89 per share, reflecting an increase of 10.6% compared to the same period last year. Revenues are forecasted to be $89.48 billion, representing a year-over-year increase of 15.9%. The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

McKesson (MCK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better than ...

McKesson (MCK) closed the most recent trading day at $508.95, moving +0.3% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.27%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq appreciated by 0.26%.The the stock of prescription drug distributor has risen by 3.92% in the past month, leading the Medical sector's loss of 4.14% and the S&P 500's gain of 2%.Investors will be eagerly watching for the performance of McKesson in its upcomi ...

The latest trading session saw McKesson (MCK) ending at $513.67, denoting a +0.86% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.The prescription drug distributor's stock has dropped by 2.03% in the past month, exceeding the Medical sector's loss of 3.35% and lagging the S&P 500's gain of 4.31%.Investors will be eagerly watching for the performance of McKesson in its upcoming ear ...

I'm a value investor who enjoys using classical value ratios to pick my portfolio. Long-term focused on low P/B, P/FCF, Owner Earnings discounting, PEG ratios, the Graham Number and an occasional net-net hunter. I also believe tracking earnings growth versus price appreciation is an essential element to any quality evaluation.I advocate self-indexing primarily using the Dow Jones Industrial Average as my index of choice combined with Joel Greenblatt's Magic Formula. This can help with tax efficiency owning ...

McKesson (MCK) closed at $488.78 in the latest trading session, marking a -1.95% move from the prior day. This change lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. The prescription drug distributor's shares have seen a decrease of 13.15% over the last month, not keeping up with the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21%. The investment community will be paying close attention to the earnings perf ...

In the latest trading session, McKesson (MCK) closed at $479.06, marking a -0.02% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0.62%, while the tech-heavy Nasdaq added 0.6%.Prior to today's trading, shares of the prescription drug distributor had lost 13.93% over the past month. This has lagged the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71% in that time.Analysts and investors alike will be keeping a close eye o ...

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this prescription drug distributor have returned -13.9%, compared to the Zacks S&P 500 composite's +1.7% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has lost 2.8%. The key question now is: What could be the stock's future direction?While m ...

The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally. After a rapid move lower, shares of McKesson Corporation MCKhave become oversold. They have also reached a price level that may provide support. This is why our team of trading experts has made it our Stock of the Day. The red line on the chart below is called a Bollinger Band. It is two standard deviations below the 20-day moving average. According to statistics and ...

Core Insights - McKesson Corporation is positioned for growth due to its strong Biologics business and positive fiscal Q1 2025 performance, despite facing competition and pricing pressures in the generic pharmaceutical market [1] - Over the past year, McKesson shares have increased by 36.1%, outperforming the industry and the S&P 500 [1] - The company has a market capitalization of $64.64 billion and anticipates a 13.4% growth over the next five years [1] Growth Drivers - The Biologics segment is a key growth area, with recent partnerships enhancing its market position, including exclusive agreements with Sentynl Therapeutics and Geron Corporation [2] - McKesson is actively pursuing acquisitions and divestitures to focus on oncology and biopharma services, including the sale of its Rexall and Well.ca businesses and acquiring a controlling interest in Core Ventures [3][4] Financial Performance - McKesson's fiscal Q1 2025 results were mixed, with earnings exceeding estimates but revenues falling short, driven by strong demand in the U.S. pharmaceutical segment [4] - The company experienced a decline in gross profit and margin, attributed to lower COVID-19-related sales and divestitures in Europe [5] Market Challenges - The Distribution Solutions segment faces significant competition from various wholesalers and logistics companies, limiting pricing negotiation power due to reliance on fewer suppliers [5] - Despite these challenges, McKesson has seen a positive estimate revision trend, with a 1.9% increase in the Zacks Consensus Estimate for earnings per share over the past 90 days [6] Revenue Projections - The Zacks Consensus Estimate for Q2 fiscal 2025 revenues is projected at $89.57 billion, reflecting a 16% increase from the previous year [6]